ACM Global Central Lab, the central laboratory that continually defines the customer-service standard with its flexible approach, has announced the launch of a liquid nitrogen based dry-vapor shipping solution in collaboration with Cryoport, Inc, a leading provider of frozen shipping solutions for the global life sciences industry.

After a 6-month effort to validate both technological elements and international regulatory capabilities, ACM  confirms that Cryoport’s dry-vapor technology is in compliance with the stringent global regulatory standards and stable temperature profiles to ensure specimen viability. As part of ACM’s comprehensive validation effort, the company assessed the movement and temperature profile of almost 600 unique specimens over a multitude of shipping lanes, including international clinical trial hubs in India, China, Southeast Asia and Europe. ACM is now offering this cold chain shipping solution at significant cost savings compared to dry ice shipping methods to its global customers.

The reusable CryoPort Express LN2 Dry Vapor Shipper is designed to meet the needs of clinical labs, diagnostic companies, research organizations, and the biotech and pharmaceutical industries by allowing tissue samples, blood and other biological material to remain frozen at or below -150ºC for 10+ days, in contrast to the current industry practice of dry-ice packaging, which often requires re-icing during transit.

“ACM is proud to move this innovative technology into production mode. With international courier costs consuming a significant portion of all global protocol budgets, we believe this new service offering from Cryoport can be an attractive and innovative alternative. Not only is the actual shipment more cost effective, the increased cost of adding more dry ice during transit to protect specimen integrity is eliminated,” said Tracy Hendershott, ACM Global’s vice president of clinical trials. “Cryoport has been extremely collaborative  in complying with ACM’s stringent validation efforts, and now we look forward to sharing that benefit with our global clients.”

“Cryoport is very pleased to enter this collaboration with ACM, an acknowledged leader and innovator in the Central Labs domain,” said Larry Stambaugh, CryoPort chief executive officer. “Our core technologies - the LN2 dry vapor shipper and Cryoportal Logistics Management platform - plus our turnkey approach to service, offer ACM and their sponsor clients a reliable and proven option to more effectively meet their clinical development goals.”

ACM Global Central Lab offers a flexible approach and a focus on precision to keep clinical research studies on schedule. ACM’s services extend to more than 60 countries with all tests conducted and managed from central lab facilities with seamless data management providing a single database. The organization performs 13 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.